AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00289185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRActHib™
Description: 3-dose intramuscular injection in the thigh.
Study NCT02862574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNF Inhibitor
Description: An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
Study NCT03759496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass
Study NCT05073965 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Subjects were assigned to receive a 1000IU vitamin D supplement dose
Study NCT05073965 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject were assigned to receive a placebo
Study NCT01129180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given SC
Study NCT03276182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipiview 2
Description: Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
Study NCT03981874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephonic interview
Description: Telephonic interview
Study NCT02068144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry Extract
Description: Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
Study NCT01129180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT01129180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Correlative studies
Description: Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
Study NCT01461512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heme arginate administration
Description: heme arginate 1 mg/kg body weight 24 hours prior to ischemia
Study NCT01461512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: NaCl isotonic
Study NCT01717703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Study NCT01717703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit drink
Study NCT01717703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cola
Study NCT02068144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
Study NCT00565565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552
Description: Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
Study NCT01717703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1% chocolate milk
Study NCT00576251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin 0.3%/Dexamethasone 0.05%
Description: Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
Study NCT03201861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: weekly paclitaxel and cisplatin
Study NCT00576251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOBRADEX
Description: TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
Study NCT04615702 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum lipase or amylase
Description: Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) is helpful in diagnosis~Acute pancreatitis is diagnosed when two of three criteria are present including:~1. Clinically (abdominal pain consistent with acute pancreatitis),~2. Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits)~3. Imaging criteria of acute pancreatitis
Study NCT04615702 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: helpful in diagnosis of acute pancreatitis and its etiology (Gallstones)
Study NCT04615702 — intervention group
Intervention type: DEVICE
Intervention: CT
Description: helpful in diagnosis of acute pancreatitis and its etiology . assist in detection of type and severity of acute pancreatitis
Study NCT04615702 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.
Description: help in diagnosis of the etiology of acute pancreatitis elevated Bilirubin, ALT, AST and alkaline phosphatase suggest biliary pancreatitis
Study NCT04615702 — intervention group
Intervention type: DEVICE
Intervention: EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)
Description: helpful in idiopathic acute pancreatitis diagnosis
Study NCT04615702 — intervention group
Intervention type: DRUG
Intervention: Ringer lactate
Description: The initial infusion rate for mild cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~* A mean arterial pressure of 65mmHg or more,~* Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters.
Study NCT04615702 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: NSAID / paracetamol +/- opiates+/- epidural analgesia
Description: Pain control (Modified World Health organization (WHO) analgesia ladder) Step1: NSAID / paracetamol Paracetamol 1gm IV infusion /8h + Diclofenac sodium 75mg /12h.~Step 2: Opiates +/- NSAID/ paracetamol Pethidine 25 mg IV/4h~Step 3: Interventional treatment (epidural analgesia) +/- opiates +/- NSAID/ paracetamol In case of severe pain not responding to the above analgesia
Study NCT04615702 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Quinolones + Metronidazole /Carbapenems ± Metronidazole
Description: * Mild attack: no antibiotic prophylaxis administered.~* Severe attack:~* Timing: Antibiotic prophylaxis administered to cases presented early within 72 hrs of disease onset.~* Duration: Not more than 2 weeks~* Antibiotics given:~  * Quinolones + Metronidazole ( the 1st choice in ward) Ciprofloxacin 400mg IV /12 h + metronidazole 500mg IV/8h~ * Carbapenems ± Metronidazole (the 1st choice in ICU patients and in case of sensitivity to quinolones) Imipenem .5gm IV/6h + metronidazole 500mg IV/8h~    b. Therapeutic (in cases with pancreatic or extrapancreatic infections)~ * In case of pancreatic infection, Carbapenems ± metronidazole were given.
Study NCT04615702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Fresubin 2Kcal fiber drink
Description: Severe cases Timing: Within at least 48 hrs of admission provided that there are no intestinal complications.~Route: Nasogastric tube Nutrients: Polymeric feeding formula~* Nutrient: Fresubin 2Kcal fiber drink 200ml (2Kcal/ml)~* Total caloric requirements ꞊ body weight (kg) X 30Kcal/day Pattern : Continuous infusion~* The nutrition started with small amount and increased gradually over 16hrs~* Infusion rate ꞊ Total caloric requirements / 16hrs
Study NCT04615702 — intervention group
Intervention type: DEVICE
Intervention: nasogastric tube
Description: in case of ileus or vomiting
Study NCT04615702 — intervention group
Intervention type: PROCEDURE
Intervention: retroperitoneal necrosectomy
Description: * General anesthesia , Supine position with 30 degree tilt towards the right side~* A left subcostal 5 cm incision is performed one finger below the left costal margin over the midaxillary line and the muscles were divided sequentially~* Then, aspiration is done from the possible collection.~* After confirmation that it was the site of the collection, the fibrotic thick wall was opened by a scissor, as the collection is opened, pus drained spontaneously.~* At first, a wide suction was introduced in the cavity and the friable loose necrotic tissue was aspirated. Then, a circuit of flushing saline was created in the residual cavity by injection of saline through the previously placed PCD followed by aspiration of the saline and detached loose necrotic tissue fragments by the wide suction tube~* After completion of the procedure, large bore surgical drain was placed into the collection. The fascia was closed over the drains. The skin closed by interrupted sutures
Study NCT04615702 — intervention group
Intervention type: PROCEDURE
Intervention: open necrosectomy
Description: Open necrosectomy was done after failure of the minimally invasive techniques. The procedure was done under general anesthesia under the coverage of Tienam (.5gm/6h IV) following the results of culture and sensitivity of the percutaneous drain effluent Surgical exploration of the peritoneal cavity was done through midline exploratory incision, there were 2 large pus collections extending from the Rt. and Lt. Lumber regions deep down into the pelvis, the intervening septa were divided and the pus was aspirated by a wide suction drain.~The lesser sac was opened and necrosectomy was done The previously placed PCD repositioned in the site of necrosectomy as a port for continuous irrigation while a wide tube drain was placed in the lesser sac for drainage. Another 2 tube drains were placed in the pelvis.
Study NCT04615702 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic transmural cystogastrostomy
Description: for pancreatic pseudocyst Antibiotic prophylaxis with Ciprofloxacin 400mg IV /12 hour was administered before the procedure and continued for 5 days after the procedure At first the cyst morphology was evaluated by EUS and color Doppler ultrasound is used to identify nearby vessels The puncture was performed using a 19-gauge needle, which was introduced into the pseudocyst via a therapeutic linear array echoendoscope. Then, a 0.035-inch guidewire was introduced through the needle and coiled within the pseudocyst under fluoroscopic guidance.~The needle was removed and a 10F cystotome was advanced over the guidewire and the tract was dilated by the cystotome, after dilatation, a 10F double-pigtail stent was placed and a sample of the aspirate is sent for chemical and microbiological analysis
Study NCT04615702 — intervention group
Intervention type: PROCEDURE
Intervention: open cystogastrostomy
Description: for pancreatic pseudocyst general anesthesia, 1 gm of cefotax was given IV at the induction of anaesthesia, supine position over the operating table A transverse supraumbilical incision was performed. A 5 cm horizontal anterior gastrotomy was performed (Image 23a). Hemostasis of the submucosal vessels was performed before the incision of the gastric mucosa.~First, the cyst was punctured followed by an incision of 5 cm at the posterior gastric wall. Aspiration of the cyst content was done for chemical and microbiological analysis The wall of the pseudocyst is hemmed to the gastric wall with continuous sutures made of a vicryl 2/0 alongside the entire circumference of the orifice Nasogastric tube was placed in the stomach. The procedure was completed by suturing the anterior gastrotomy with a vicryl 2/0 continous sutures in 2 layers A tube drain was inserted at the pelvis with closure of the abdominal wound in a standard way.
Study NCT04615702 — intervention group
Intervention type: PROCEDURE
Intervention: percutaneous catheter drainage (PCD) for infected necrosis
Description: PCD~* The percutaneous drainage catheter placed through peritoneal approach under US guidance, the drain size was 12 F.~* After placement of the percutaneous catheter, aspirate was sent for microbiological assessment~* The PCD was flushed with 50 ml saline, three times daily to keep the drain open and improve lavage of the collection
Study NCT04615702 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound (EUS) guided aspiration for infected necrosis
Description: endoscopic approach it was done to one patient in the form of EUS guided aspiration of pus in a case with infected necrosis followed by percutaneous US guided aspiration of the residual
Study NCT01814488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic transplant
Description: Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.~The conditioning regimen in standard use is:~Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;~Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;~Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.~Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if \<40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice.
Study NCT03201861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC to docetaxel or paclitaxel
Description: Standard adjuvant chemotherapy recommended by guideline
Study NCT02299752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-gloving system
Description: single-gloving system was used during Catheterization
Study NCT01124448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius PS2
Description: 9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
Study NCT02299752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double-gloving system
Description: double-gloving system was used during Catheterization. inner and outer gloves were the same size
Study NCT01124448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius PS2
Description: 9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
Study NCT02193256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Titrated over 1 week to a maximum dose of 2mg/day
Study NCT02193256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Titrated over 1 week to a maximum dose of 2mg/day
Study NCT02193256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Titrated over 3 weeks to a maximum dose of 8mg/day
Study NCT02193256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03284255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: study group
Description: study group in which patient will accept the treatment of Bioresorbable Coronary Stent
Study NCT03284255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
Study NCT03314714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute bout of endurance exercise
Description: Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
Study NCT02287701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Simultaneous PET/MRI (3T system)
Study NCT03930641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTH258
Description: 6 mg in prefilled syringe
Study NCT03849976 — intervention group
Intervention type: BEHAVIORAL
Intervention: Therapeutic communication
Description: Patients will be accompanied to the operating room by a stretcher bearer trained in therapeutic communication
Study NCT05707624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video education
Description: In the study, there are 2 groups in total: the intervention group (n=50) which videos of approaching the febrile child was watched once a week and 2 videos, and the control group (n=49) which no other application is made except for the routine procedure of the hospital
Study NCT05707624 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the routine procedure
Description: the routine procedure
Study NCT01897272 — intervention group
Intervention type: BEHAVIORAL
Intervention: Splinting
Description: One group will have their wrist splinted after their carpal tunnel release surgery.
Study NCT00087880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion and NRT
Description: All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
Study NCT00087880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion and NRT
Description: All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
Study NCT03817060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreservation of embryos at cleavage stage
Description: cryopreservation of embryos at cleavage stage (day 3) of embryo development
Study NCT03817060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreservation of embryos at blastocyst stage
Description: cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development
Study NCT03482635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion
Study NCT03482635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for infusion
Study NCT02769858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: Light therapy glasses
Study NCT01651546 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intermittent catheterization test
Description: I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
Study NCT04235452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Somatosensory evoked potential
Description: Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out.
Study NCT03421756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
Study NCT03421756 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.
Study NCT03421756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
Study NCT04027374 — intervention group
Intervention type: PROCEDURE
Intervention: Fetal surgery for MMC repair
Description: Fetal surgery for MMC repair
Study NCT04529330 — intervention group
Intervention type: PROCEDURE
Intervention: fasciotomy
Description: if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS
Study NCT00732420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Topoisomerase I inhibition.
Study NCT00732420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Tyrosine kinase inhibitor
Study NCT00444457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
Study NCT00444457 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7vPnC
Description: 0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
Study NCT04508036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Withdrawal of blood samples for D-Dimer
Description: Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for D-dimer levels.
Study NCT04508036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Withdrawal of blood samples for Fibrinogen
Description: Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for Fibrinogen levels.
Study NCT04508036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiographic Examination
Description: At postnatal 3rd, 7th and 14th days, Ductus Arteriosus will be echocardiographically examined to obtain calculations and confirm status of ductal patency or closure.
Study NCT01644136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo standard robotic assisted laparoscopic prostatectomy